UnknownPhase 1NCT04556669

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Studying Sarcoma of cervix uteri

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Principal Investigator
Zhiyu Wang, M.D
Hebei Medical University Fourth Hospital
Intervention
Autologous aPD-L1 armored anti-CD22 CAR T cells(biological)
Enrollment
30 enrolled
Eligibility
18-75 years · All sexes
Timeline
20202025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04556669 on ClinicalTrials.gov

Other trials for Sarcoma of cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Sarcoma of cervix uteri

← Back to all trials